N-(3,4-二甲氧基苄基)脲 | 65609-19-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3,4-二甲氧基苄基)脲
• 英文名称: 1-(3,4-dimethoxybenzyl)urea
• 英文别名: (3,4-dimethoxybenzyl)urea；N-(3,4-dimethoxybenzyl) urea；n-veratrylurea；N-(3,4-dimethoxybenzyl)urea；(3,4-dimethoxyphenyl)methylurea
• CAS: 65609-19-0
• 化学式: C₁₀H₁₄N₂O₃
• mdl: MFCD01314629
• 分子量: 210.233
• InChiKey: MCKXSAZGGFLRTR-UHFFFAOYSA-N

物化性质

• 熔点：
  183-185°
• 沸点：
  352.7±42.0 °C(Predicted)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(3,4-二甲氧基苄基)脲 在 氢氧化钾 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 11.0h， 生成 Ethyl 1-(3,4-dimethoxylbenzyl)-2,4,5-trioxoimidazolidine-3-acetate
  参考文献：
  名称：

  Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids

  摘要：

  A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.

  DOI：

  10.1021/jm9508393
• 作为产物：
  描述：

  potassium cyanate 、 3,4-二甲氧基苯甲酰胺盐酸盐 以 水 为溶剂， 生成 N-(3,4-二甲氧基苄基)脲
  参考文献：
  名称：

  Borgna; Vicarini; Carmellino, Farmaco, Edizione Scientifica, 1980, vol. 35, # 12, p. 1034 - 1038

  摘要：

  DOI：

文献信息

• [EN] NOVEL COMPOUNDS THAT ARE ERK INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS QUI SONT DES INHIBITEURS D'ERK
  申请人：MERCK SHARP & DOHME

  公开号：WO2013063214A1

  公开（公告）日：2013-05-02

  Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).

  公开的是具有式(1)的ERK抑制剂及其药学上可接受的盐。还公开了使用式(1)的化合物治疗癌症的方法。
• MONOSUBSTITUTED UREA DERIVATIVES AS A SELF-TANNING SUBSTANCE
  申请人：MERCK PATENT GMBH

  公开号：US20200038304A1

  公开（公告）日：2020-02-06

  The present invention relates to the use of monosubstiuted urea derivatives of the formula I as self-tanning substance, for increasing melanin synthesis, for improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these urea derivatives.

  本发明涉及使用式I的单取代脲衍生物作为自日晒剂，用于增加黑色素合成，改善黑色素运输和/或改善黑色素在基底层上方的分布，以及包含这些脲衍生物的制剂。
• 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
  申请人：——

  公开号：US20030171384A1

  公开（公告）日：2003-09-11

  A compound of formula (I) in free or salt form, where R 1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino, R 3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 4 is hydrogen or alkyl, R 5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula —N(R 6 )R 7 , aryl optionally substituted by one or more substituents selected from halogen or alkoxy, or heteroaryl having 5 or 6 ring atoms attached through a ring carbon atom to the indicated carbon atom, and R 6 and R 7 are each independently hydrogen or alkyl optionally substituted by hydroxy or alkoxy or one of R 6 and R 7 is hydrogen and the other is acyl, or R 6 and R 7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclyl group.

  化合物的结构式(I)在自由或盐形式下，其中R1为氢或烷基，可以选择地被羟基、烷氧基或烷硫基取代，R2为氢、烷基、羟基烷基、烷基羰基氧基烷基、烷氧基烷基、烷硫基烷基、烯基、环烷基烷基、杂环烷基烷基、芳基烷基，其中芳环可以选择地与一个5-成员杂环基团融合，或可以选择地被烷氧基、氨基、烷基氨基、二烷基氨基、酰胺基、卤素、羟基、氨基磺酰基、烷基氨基磺酰基、二烷基氨基磺酰基、烷基磺酰氨基或二烷基氨基磺酰氨基等一个或多个取代基取代，R3为氢或烷基，可以选择地被羟基、烷氧基或烷硫基取代，R4为氢或烷基，R5为喹啉基、异喹啉基或氧代二氢异喹啉基，可以选择地与一个5-成员杂环基团融合，并可以选择地被卤素、氰基、羟基、烷基、羟基烷基、烷氧基烷基、烷硫基烷基、烷氧基、烷硫基、烯基、烷氧羰基、炔基、羧基、酰基、一个结构式为—N(R6)R7的基团、可以选择地被卤素或烷氧基等一个或多个取代基取代的芳基，或者通过一个环碳原子连接到所指示的碳原子的5个或6个环原子的杂芳基，R6和R7分别独立地为氢或烷基，可以选择地被羟基或烷氧基取代，或者R6和R7中的一个为氢，另一个为酰基，或者R6和R7与它们连接的氮原子一起表示一个5-或6-成员杂环基团。
• Combinations
  申请人：——

  公开号：US20030114469A1

  公开（公告）日：2003-06-19

  The present invention relates to a pharmaceutical composition, comprising (a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A reductase inhibitors; (iii) an anti-hypertensive agent; and (iv) a serotonin reuptake inhibitor (SSRI) or, in each case, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

  本发明涉及一种药物组合物，包括(a) 磷酸二酯酶5抑制剂或其药用盐，以及(b) 来自以下组中选择的至少一种活性成分(i) 抗糖尿病药物；(ii) HMG-Co-A还原酶抑制剂；(iii) 抗高血压药物；和(iv) 血清素再摄取抑制剂（SSRI）或在每种情况下，其药用盐；以及药学上可接受的载体。该药物组合物可用于治疗性功能障碍、高血糖、高胰岛素血症、高脂血症、高甘油三酯血症、糖尿病、胰岛素抵抗、糖代谢受损、糖耐量受损（IGT）病状、空腹血糖受损病状、肥胖、糖尿病视网膜病、糖尿病肾病、肾小球硬化、糖尿病神经病变、X综合征、勃起功能障碍、冠心病、高血压，尤其是高收缩压高血压（ISH），心绞痛、心肌梗死、中风、血管再狭窄、内皮功能障碍、血管顺应性受损、充血性心力衰竭。
• Process for preparing 1-substituted 5-hydroxy-imidazoline-2,4-diones and 1-substituted 5-alkoxy-imidazoline-2,4-diones
  申请人：Bayer Aktiengesellschaft

  公开号：US06365752B1

  公开（公告）日：2002-04-02

  A process for preparing specific 1-substituted 5-hydroxy-imidazoline-2,4-diones by reacting glyoxylic acid with N-substituted ureas is provided, where this process is carried out in a 10-80% strength aqueous solution and in the presence of an acid catalyst. The 1-substituted 5-hydroxy-imidazoline-2,4-diones can subsequently be converted in a further reaction step to give 1-substituted 5-alkoxy-imidazoline-2,4-diones.

  提供一种制备特定的1-取代的5-羟基咪唑啉-2,4-二酮的方法，该方法通过将乙醛酸与N-取代脲反应，在10-80%浓度的水溶液中，在酸催化剂的存在下进行。随后，1-取代的5-羟基咪唑啉-2,4-二酮可以在进一步的反应步骤中转化为1-取代的5-烷氧基咪唑啉-2,4-二酮。